Drug intelligence / Profile preview

buddlejasaponin IV

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

Buddlejasaponin IV is a triterpenoid saponin isolated from the medicinal plant *Clinopodium chinense var. shibetchense*. It has been investigated for its antineoplastic properties, particularly its ability to overcome resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). The compound exerts its effects by suppressing the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway, which leads to the inhibition of cancer cell proliferation and migration. Research specifically highlights its potential in treating gefitinib-resistant NSCLC cell lines, suggesting a role in targeted therapy for advanced lung cancers.

Other names: Buddlejasaponin IV

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on buddlejasaponin IV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on buddlejasaponin IV.

Explore the full profile